Search Results 1801-1810 of 16443 for Maximum

  1. Neurology - Clinical trials - Mayo Clinic

    The purpose of phase 1 of this trial is to determine the maximum tolerated dose of temozolomide followed by selinexor in recurrent glioblastoma patients as ...

  2. Neurology - Clinical trials - Mayo Clinic

    The purpose of phase 1 of this trial is to determine the maximum tolerated dose of temozolomide followed by selinexor in recurrent glioblastoma patients as ...

  3. Neurology - Clinical trials - Mayo Clinic

    The purpose of phase 1 of this trial is to determine the maximum tolerated dose of temozolomide followed by selinexor in recurrent glioblastoma patients as ...

  4. Neurology - Clinical trials - Mayo Clinic

    The purpose of phase 1 of this trial is to determine the maximum tolerated dose of temozolomide followed by selinexor in recurrent glioblastoma patients as ...

  5. Neurology - Clinical trials - Mayo Clinic

    The purpose of phase 1 of this trial is to determine the maximum tolerated dose of temozolomide followed by selinexor in recurrent glioblastoma patients as ...

  6. A Study to Evaluate Parsaclisib (INCB050465), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine And Prednisone (Par-CHOP) Immunochemotherapy for Patients with Newly Diagnosed High Risk Diffuse Large B-Cell Lymphoma - Mayo Clinic

    The primary purpose of this study in the dose-finding phase is to establish the maximum tolerated dose (MTD) of parsaclisib in combination with R-CHOP in ...

  7. A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva - Mayo Clinic

    ... maximum (SUVmax) of individual active HO site(s) by PET - To compare the effect of REGN2477 versus placebo on pain due to FOP, as measured by the area under ...

  8. Ranolazine For Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI) - Mayo Clinic

    ... maximum total of 1000 mg daily (additional anti-diabetic medications may be added as clinically indicated to allow subjects to decrease their metformin dose ...

  9. First-in-Human Study of KO-947 in Non-Hematological Malignancies - Mayo Clinic

    This phase 1 first-in-human (FIH) dose escalation study will determine the maximum tolerated dose (MTD) of KO-947 in subjects with locally advanced ...

  10. Gastroenterology and Hepatology - Clinical trials

    Difference in gastric emptying (T1/2, emptying at 2h and emptying at 4h);; Volume to fullness (sensation of usual postprandial fullness) and maximum feeling of ...